๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy

โœ Scribed by James Carmichael; AdrianL. Harris

Publisher
Springer
Year
2004
Tongue
English
Weight
185 KB
Volume
53
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Open-label comparison of the antiemetic
Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy
โœ Coppes, Max J.; Lau, Robert; Ingram, Lewis C.; Wiernikowski, John T.; Grant, Ron ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 81 KB

Background. Nausea and vomiting are among the most unpleasant adverse side effects of cancer therapy. Procedure. An open-label dose-escalation study was conducted to assess the appropriate intravenous dose of dolasetron for pediatric patients undergoing chemotherapy. Patients received dolasetron in

A double-blind comparison of the efficac
A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy
โœ David S. Ettinger; Peter D. Eisenberg; David Fitts; Carl Friedman; Karen Wilson- ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 848 KB

The purpose of this study was to define an optimal administration schedule of granisetron for patients receiving moderately ernetogenic chemotherapy by comparing the antiemetic efficacy and safety of 2 mg of the drug administered orally. ## METHODS. In this double-blind, randomized, parallel stud